A study of of CT303 in patients with acute respiratory distress syndrome

GC Cell Corporation is recruiting patients for the clinical trial of Phase I Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of CT303 in Patients With ARDS.

This study is a multi-center, open-label, dose-escalation and dose-finding phase 1 clinical trial. The primary purpose is to evaluate the safety and tolerability of CT303 and the Secondary purpose is to evaluate the efficacy of CT303 in patients with ARDS. And the exploratory purpose is to evaluate pharmacodynamics properties pharmacokinetic properties of CT303 in patients with ARDS.

The researchers plan that January 26, 2022 will be the study start date. The indicative completion of the clinical trial will be expected in October 18, 2024.

Among primary outcome measures are the Adverse Drug Reaction incidence rate and Evaluate safety through the incidence rate of adverse drug reactions corresponding to criteria for stopping the dose increasing.

The page dedicated to this clinical trial can be found here: https://ichgcp.net/clinical-trials-registry/NCT05238532.